From a clinical point of view, KRAS-mutant cancers have generally been associated with poorer overall survival (OS) compared to KRAS wild type tumors, especially in the advanced stages (18–20); however, other studies in early (where the benefit of adjuvant chemotherapy is minimal) or advanced stage of KRAS-mutant lung cancer have provided conflicting results, thus the prognostic value of KRAS alteration is still debated (21–23). The gene discussed is KRAS; the disease is lung carcinoma.